HRT3 Antibody

What is HRT3 and what cellular functions does it perform?

HRT3, also designated as HEYL (Hairy/enhancer-of-split related with YRPW motif-like), belongs to the Hairy-related transcription factors (HRTs) family, which are a subclass of basic helix-loop-helix (bHLH) proteins that function as transcriptional repressors. HRT3 exhibits structural similarity with the Hairy/Enhancer of split [H/E(spl)] proteins and contains both a bHLH domain and an Orange domain, though notably it lacks the YRPW domain present in other HRT family members . The HRT3 gene maps to human chromosome 1p34.2 and functions as a downstream target in the Notch signaling pathway, playing a critical role in developmental processes .

In biological systems, HRT3 is predominantly expressed in developing somites, heart, and nervous system tissues during embryonic development, suggesting its importance in the proper formation and differentiation of these structures . As a transcriptional regulator, HRT3 participates in cell fate decisions and boundary establishment of gene expression patterns. The specific transcriptional targets of HRT3 and its regulatory mechanisms continue to be active areas of research in developmental biology and disease studies.

How does the HRT3 Antibody (3555C3a) differ from other antibodies targeting related proteins?

The HRT3 Antibody (3555C3a) is an IgG1 mouse monoclonal antibody specifically designed to detect the human HRT3 protein using western blot (WB) and immunoprecipitation (IP) techniques . Unlike polyclonal antibodies that might recognize multiple epitopes, this monoclonal antibody binds to a specific epitope on the HRT3 protein, offering higher specificity for research applications. The antibody demonstrates specificity for HRT3 protein of human origin, making it particularly valuable for studies involving human cell lines and tissue samples .

When compared to antibodies targeting other HRT family members (HRT1 and HRT2), the 3555C3a antibody maintains high specificity for HRT3 despite the structural similarities between these related proteins. This specificity is crucial because HRT family members, while similar, have distinct expression patterns and potentially different functions in various tissues. Researchers should note that this antibody is optimized for detection methods like western blotting and immunoprecipitation, though adaptation protocols for immunohistochemistry or flow cytometry may be developed by individual laboratories with appropriate validation.

What is the relationship between HRT3 and the Notch signaling pathway in developmental processes?

HRT3 functions as a downstream effector in the Notch signaling pathway, which plays a fundamental role in cell fate determination and developmental patterning . The LIN-12/Notch family of transmembrane receptors activates transcription of Hairy/Enhancer of split [H/E(spl)] genes, including the HRT family, which then act as transcriptional repressors to influence gene expression patterns during development . This regulatory cascade is critical for establishing boundaries of gene expression and directing proper embryonic development.

In the context of Notch signaling, HRT3 likely acts as a transcriptional repressor that helps translate Notch receptor activation into specific cellular responses. The expression of HRT3 in developing somites, heart, and nervous system indicates its involvement in the differentiation and patterning of these tissues through Notch-mediated processes . Perturbations in this signaling axis can lead to developmental abnormalities, highlighting the importance of proper HRT3 function. Researchers investigating developmental processes or diseases involving dysregulation of Notch signaling often examine HRT3 expression patterns as an indicator of pathway activity.

How does the absence of the YRPW domain in HRT3 impact its functional properties compared to other HRT family members?

The distinctive feature of HRT3 among the HRT family is its lack of the YRPW domain, which is present in both HRT1 and HRT2 . This structural difference likely contributes to functional divergence in the family, potentially affecting protein-protein interactions, DNA binding affinity, or transcriptional repression mechanisms. The YRPW motif in other HRT proteins is thought to mediate specific molecular interactions that may influence recruitment of co-repressors or other transcriptional machinery components to target gene promoters.

Without the YRPW domain, HRT3 may employ alternative mechanisms for transcriptional regulation or interact with a different set of co-factors compared to its family members. This functional specialization could explain why HRT3 has distinct roles in certain developmental processes despite overlapping expression patterns with HRT1 and HRT2. Researchers investigating the molecular mechanisms of HRT family function should consider these structural differences when interpreting experimental results or designing functional studies. Comparative analysis between HRT family members using techniques such as co-immunoprecipitation followed by mass spectrometry has potential to reveal unique protein interaction networks associated with HRT3's distinct domain architecture.

What are the key technical considerations when optimizing western blot protocols for HRT3 detection?

When optimizing western blot protocols for HRT3 detection using the 3555C3a antibody, researchers should pay particular attention to several technical factors that influence detection sensitivity and specificity. Sample preparation requires careful consideration, as HRT3 is a transcription factor typically present at relatively low abundance in cells. Efficient nuclear protein extraction protocols with appropriate protease inhibitors are essential to preserve HRT3 integrity during sample preparation . Standard RIPA buffer supplemented with DTT (1mM) and protease inhibitor cocktail provides a good starting point for extraction.

Transfer conditions also warrant optimization, as HRT3 (approximately 22kDa) may require adjustments to standard protocols. A semi-dry transfer system using PVDF membrane with 0.2μm pore size (rather than 0.45μm) often improves retention of smaller proteins like HRT3. Blocking solutions should be tested empirically, with 5% non-fat dry milk in TBST generally providing adequate blocking while maintaining antibody binding capacity. The recommended dilution for HRT3 Antibody (3555C3a) typically ranges from 1:500 to 1:2000, though this should be optimized for each specific application and detection system. Overnight incubation at 4°C often yields better results than shorter incubations at room temperature for low-abundance proteins like HRT3.

How can researchers differentiate between HRT3 and other HRT family members in experimental systems?

Differentiating between HRT3 and other closely related HRT family members requires a multi-faceted approach combining complementary techniques. While the HRT3 Antibody (3555C3a) offers specificity for HRT3, validation of this specificity is crucial, particularly in systems where multiple HRT proteins are expressed . Researchers should consider including positive controls (cells known to express HRT3) and negative controls (cells with confirmed absence of HRT3 expression) in their experimental design to establish baseline detection parameters.

For definitive differentiation, molecular techniques targeting the unique domains of HRT3 provide valuable complementary evidence. PCR primers designed to amplify the region corresponding to the YRPW domain (absent in HRT3 but present in HRT1/2) can help distinguish between family members at the mRNA level . siRNA-mediated knockdown experiments using HRT3-specific siRNAs, followed by western blotting with the 3555C3a antibody, can confirm antibody specificity and rule out cross-reactivity with other HRT members. In addition, mass spectrometry analysis of immunoprecipitated proteins can provide unambiguous identification of HRT3 based on unique peptide sequences not shared with other family members. This multi-method approach ensures reliable differentiation between closely related HRT family proteins.

What controls should be included when using HRT3 antibody in research experiments?

When designing experiments using the HRT3 Antibody (3555C3a), researchers should implement a comprehensive set of controls to ensure valid and interpretable results. Positive controls should include cell lines or tissues with confirmed HRT3 expression, such as certain cardiomyocyte lineages or neural progenitor cells where HRT3 plays developmental roles . These positive controls establish the expected band pattern and intensity for comparison with experimental samples. Negative controls should incorporate cell lines lacking HRT3 expression or samples where HRT3 has been knocked down using siRNA or CRISPR-Cas9 approaches.

Additional controls should address potential technical artifacts. Loading controls using housekeeping proteins appropriate for the cellular compartment being analyzed (e.g., Lamin B for nuclear fractions where HRT3 would be expected) confirm equal protein loading and transfer efficiency. Antibody specificity controls, such as pre-absorption with recombinant HRT3 protein, can validate signal specificity by demonstrating signal reduction when the antibody's binding sites are blocked. For immunoprecipitation experiments, researchers should include "no antibody" and "isotype control antibody" conditions to identify non-specific binding. These comprehensive controls collectively strengthen data interpretation and enhance reproducibility across different experimental systems.

What sample preparation methods are recommended for optimal HRT3 detection in different applications?

Sample preparation for HRT3 detection requires protocols optimized for nuclear proteins, as HRT3 functions as a transcription factor primarily localized to the nucleus . For western blot applications, nuclear extraction protocols yield better results than whole-cell lysates, as they concentrate the nuclear protein fraction where HRT3 is predominantly found. Commercial nuclear extraction kits provide standardized methods, though classical protocols using hypotonic/hypertonic buffer systems also work effectively. Regardless of the chosen method, samples should be processed rapidly with protease inhibitors at cold temperatures (4°C) to minimize protein degradation.

For immunoprecipitation applications, crosslinking prior to cell lysis can preserve protein-protein interactions involving HRT3, which may be important for studying its transcriptional complexes. Formaldehyde (1% for 10 minutes) provides reversible crosslinking suitable for this purpose. When preparing samples for potential immunohistochemistry, fixation method significantly impacts epitope accessibility. Although not explicitly mentioned in the product information, if adapting the 3555C3a antibody for IHC, researchers should compare paraformaldehyde fixation with alternative methods like acetone or methanol fixation, as these may better preserve the epitope recognized by this antibody. Antigen retrieval methods, particularly heat-induced epitope retrieval in citrate buffer (pH 6.0), often improve detection of nuclear antigens like HRT3 in fixed tissues.

How can researchers validate cross-reactivity concerns between HRT3 and HER3 antibodies?

Epitope mapping information, when available from manufacturers, should be reviewed to ensure the recognized sequences are unique to the intended target. Immunodepletion experiments, where samples are pre-cleared with one antibody before probing with the other, can reveal any potential cross-reactivity issues. Mass spectrometry analysis of immunoprecipitated proteins provides definitive identification of the captured proteins by sequence. When ordering or citing these antibodies in publications, researchers should use the full protein name along with the abbreviation and clone number (e.g., "Anti-Hairy-related transcription factor 3 (HRT3) antibody, clone 3555C3a") to avoid confusion with HER3 antibodies that are more commonly used in cancer research contexts .

What are the optimal conditions for using HRT3 antibody in immunoprecipitation experiments?

For successful immunoprecipitation (IP) of HRT3 using the 3555C3a antibody, optimization of several parameters is essential for capturing this low-abundance transcription factor . The lysis buffer composition significantly impacts epitope accessibility and protein solubility. A recommended starting buffer consists of 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-40, with 1mM EDTA and a protease inhibitor cocktail. This mild non-ionic detergent preserves protein-protein interactions while effectively solubilizing nuclear membranes to release HRT3.

The antibody-to-lysate ratio requires careful titration, with 2-5μg of HRT3 antibody per 500μg of nuclear protein extract serving as a suitable starting point. Pre-clearing lysates with protein G beads (1 hour at 4°C) reduces non-specific binding. The antibody-lysate binding step should proceed overnight at 4°C with gentle rotation to maximize antigen capture while minimizing protein degradation. When recovering immunoprecipitated complexes, mild washing conditions (TBS with 0.1% Tween-20) preserve weaker interactions, while more stringent conditions may be needed if background is problematic. For studying HRT3's role in transcriptional complexes, researchers might consider crosslinking cells prior to lysis (1% formaldehyde, 10 minutes) followed by sonication to fragment chromatin, adapting ChIP protocols for co-IP of DNA-bound complexes.

How can HRT3 antibody be used to investigate Notch pathway regulation in developmental models?

The HRT3 antibody provides a valuable tool for investigating Notch pathway activity in developmental models, as HRT3 functions as a downstream effector of Notch signaling . In developing embryos or organoid systems, researchers can correlate HRT3 protein expression patterns with developmental stages and morphological features using western blot analysis of micro-dissected tissues. This approach allows temporal mapping of Notch activity through its effect on HRT3 expression levels. When comparing wildtype and Notch pathway mutants, HRT3 antibody detection can serve as a readout of pathway perturbation effects.

For mechanistic studies, combining HRT3 antibody with other techniques enhances experimental power. ChIP-seq experiments using the 3555C3a antibody can identify genomic binding sites of HRT3 during development, revealing direct transcriptional targets. Co-immunoprecipitation followed by mass spectrometry can uncover stage-specific protein interaction partners of HRT3 in the context of Notch signaling. Time-course experiments following Notch pathway stimulation or inhibition, with subsequent analysis of HRT3 protein levels, provide insights into the kinetics of this signaling axis. Together, these approaches enable researchers to position HRT3 precisely within the regulatory network of Notch signaling during development, potentially revealing tissue-specific or context-dependent functions.

What strategies can be employed to study HRT3 in heart and neural development research?

Given HRT3's expression in developing cardiac and neural tissues, specialized approaches can maximize the utility of HRT3 antibody in these research contexts . For cardiac development studies, microdissection of heart regions from different developmental stages followed by western blot analysis can reveal spatial and temporal dynamics of HRT3 expression. In cardiomyocyte differentiation models derived from stem cells, researchers can track HRT3 expression as a potential marker of specific differentiation stages or subtypes. Correlation with functional markers of cardiomyocyte maturation may reveal relationships between HRT3 and functional cardiac development.

In neural development research, similar stage-specific analyses in the developing central nervous system can map HRT3 expression to specific neurogenesis events. Neurosphere cultures or brain organoids provide controlled systems for manipulating HRT3 expression and observing effects on neural differentiation trajectories. Double immunostaining experiments (adapting the 3555C3a antibody for immunofluorescence with appropriate validation) could potentially reveal co-localization with neural progenitor markers or differentiated neuronal markers, providing insight into which neural cell populations express HRT3. For both cardiac and neural research, combining HRT3 detection with transcriptome analysis after pathway perturbation can help construct regulatory networks involving this transcription factor during tissue-specific development.